Study guide
14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease
Key Takeaways Explain This Topic AI
Minimal change disease is the commonest nephrotic syndrome in children, shows normal light microscopy with podocyte foot process effacement, and responds to corticosteroids.
IgA nephropathy classically causes visible haematuria within 1-2 days of an upper respiratory tract infection, in contrast to the 1-3 week latency of post-streptococcal glomerulonephritis.
Membranous nephropathy is the commonest primary nephrotic syndrome in white adults and is associated with anti-phospholipase A2 receptor antibodies.
Last updated: September 2026
Glomerular diseases represent a core test domain in MRCP(UK) Part 1. Candidates must possess detailed knowledge of clinical syndromes (nephrotic vs. nephritic), distinct histological patterns on light microscopy (LM), immunofluorescence (IF), and electron microscopy (EM), and guideline-directed immunosuppressive regimens.
1. Nephrotic Syndrome vs. Nephritic Syndrome
Glomerular pathologies typically present along a spectrum bounded by two quintessential clinical syndromes:
Nephrotic Syndrome
Defined by a classical diagnostic triad:
Heavy Proteinuria: > 3.5 g/24 hours (or urinary protein-to-creatinine ratio [PCR] > 300 mg/mmol; albumin-to-creatinine ratio [ACR] > 220 mg/mmol).
Hypoalbuminaemia: Serum albumin < 30 g/L (often < 20 g/L).
Peripheral Pitting Oedema: Dependent pitting oedema driven by secondary sodium and water retention (overfill hypothesis via renal ENaC upregulation by plasmin in filtrate) alongside reduced intravascular oncotic pressure (underfill hypothesis).
Secondary Complications of Nephrotic Syndrome:
Hypercoagulability & Thromboembolism: Urinary filtration loss of endogenous anticoagulants ( antithrombin III , protein C , and protein S ), coupled with compensatory hepatic hyper-synthesis of prothrombotic factors (fibrinogen, factors V and VIII) and thrombocytosis. Venous thromboembolism is most common in membranous nephropathy , specifically predisposing to renal vein thrombosis (manifesting as sudden flank pain, macroscopic haematuria, worsening proteinuria, or sudden decline in renal function; confirmed via CT or Doppler ultrasound). Prophylactic anticoagulation (e.g. low-molecular-weight heparin or direct oral anticoagulants) is indicated when serum albumin falls below 20–25 g/L in high-risk patients.
Hypercholesterolaemia & Dyslipidaemia: Diminished plasma oncotic pressure triggers generalized hepatic protein synthesis, markedly elevating total cholesterol, LDL, and apolipoprotein B, accompanied by defective peripheral clearance via lipoprotein lipase downregulation. Lipiduria yields oval fat bodies and "Maltese cross" birefringence under polarized light microscopy.
Infection Risk: Urinary loss of low-molecular-weight immunoglobulins (chiefly IgG) and alternative complement pathway components (Factor B). Patients are uniquely vulnerable to encapsulated bacterial infections, classically Streptococcus pneumoniae (spontaneous bacterial peritonitis, lobar pneumonia, and sepsis). Pneumococcal and seasonal influenza vaccinations are mandatory.
Nephritic Syndrome
Characterized by acute, aggressive endocapillary glomerular inflammation and disruption of the glomerular filtration barrier:
Haematuria with Active Urinary Sediment: Dysmorphic red blood cells (acanthocytes) and pathognomonic red blood cell casts .
Sub-nephrotic Proteinuria: Typically 0.5–3.0 g/24 hours.
Hypertension: Driven by impaired sodium and fluid excretion.
Oliguria & Elevated Serum Creatinine: Secondary to reduction in total functional filtration surface area.
Feature Nephrotic Syndrome Nephritic Syndrome
Primary Pathology Podocyte / visceral epithelial injury; charge and slit-diaphragm defect Glomerular inflammation, hypercellularity, capillary necrosis
Urinary Protein Heavy (> 3.5 g/24h, PCR > 300 mg/mmol) Sub-nephrotic (< 3.0 g/24h)
Haematuria & Casts Absent or microscopic; hyaline / fatty casts Marked macroscopic or microscopic; red blood cell casts , acanthocytes
Serum Albumin Severely reduced (< 30 g/L) Normal or mildly reduced
Oedema Severe, generalized (anasarca, periorbital, ascites) Mild-to-moderate (periorbital puffiness, dependent)
Blood Pressure Normal or mildly elevated Frequently hypertensive
Systemic Complications Thromboembolism (RVT, DVT, PE), hypercholesterolaemia, encapsulated sepsis Circulatory volume overload, acute pulmonary oedema, uraemia
- 2. Primary Glomerular Diseases
- Minimal Change Disease (MCD)
Epidemiology: Responsible for > 80% of nephrotic syndrome in young children (< 10 years) and 10–15% in adults.
Aetiology: Mostly idiopathic (primary T-cell immune dysregulation generating circulating permeability factors targeting nephrin/podocin). Secondary triggers: NSAID use, Hodgkin lymphoma and other lymphoproliferative malignancies (paraneoplastic cytokine storm), lithium, and atopy.
Renal Biopsy Features:
Light Microscopy (LM): Completely normal glomerular architecture ("nil disease"); tubules may contain reabsorbed lipid droplets.
Immunofluorescence (IF): Completely negative (no immune complex or complement deposition).
Electron Microscopy (EM): Pathognomonic diffuse, uniform effacement (flattening/fusion) of podocyte visceral epithelial foot processes .
Clinical Presentation & Management: Abrupt onset of profound nephrotic syndrome with selective proteinuria (primarily albumin). Highly responsive to high-dose oral corticosteroids ( oral prednisolone 1 mg/kg/day , up to 60–80 mg daily for 4–16 weeks). Over 90% achieve complete remission. Frequent relapses or steroid-dependent disease are managed with cyclophosphamide, calcineurin inhibitors (tacrolimus, ciclosporin), or rituximab.
Focal Segmental Glomerulosclerosis (FSGS)
Epidemiology: The commonest cause of primary nephrotic syndrome in adults of African descent. Strongly associated with homozygous risk alleles in the APOL1 gene (which encodes apolipoprotein L1, offering evolutionary protection against Trypanosoma brucei rhodesiense African sleeping sickness at the expense of accelerated podocyte lysosomal swelling and lysis).
Aetiology:
Primary: Circulating permeability factor (e.g. suPAR).
Secondary: Hyperfiltration from reduced nephron mass (unilateral renal agenesis, reflux nephropathy, morbid obesity), HIV-associated nephropathy (HIVAN) (characterised by the aggressive collapsing variant of FSGS), intravenous heroin abuse, and sickle cell nephropathy.
Renal Biopsy Features:
LM: Sclerosis involving a portion of the capillary tuft ( segmental ) in some, but not all, glomeruli ( focal ), predominantly initiating in juxtamedullary nephrons. Often displays hyalinosis and adhesion to Bowman's capsule.
IF: Non-specific trapping of IgM and C3 within sclerotic segments.
EM: Extensive podocyte foot process effacement with focal areas of podocyte detachment from the underlying bare basement membrane.
Management: Poor response to corticosteroids compared to MCD (< 30–50% complete response). Calcineurin inhibitors (tacrolimus), RAAS blockade, and SGLT2 inhibitors. High allograft recurrence: Recur in 30–40% of renal allografts post-transplantation, often within hours to days of engraftment due to the circulating permeability factor.
Membranous Nephropathy (MN)
Epidemiology: The commonest cause of primary nephrotic syndrome in Caucasian adults (peak incidence between 40 and 60 years).
Pathogenesis: In 70–80% of primary cases, circulating autoantibodies (chiefly IgG4) target the M-type phospholipase A2 receptor (anti-PLA2R) on the visceral podocyte surface. Autoantibodies against thrombospondin type-1 domain-containing 7A (THSD7A) account for another 3–5%. In situ immune complex formation activates complement, forming the sublytic membrane attack complex (C5b-9) which injures the podocyte.
Secondary Causes (~20–25%): Solid organ malignancies (carcinomas of the lung, prostate, colon, stomach, and breast; age > 60 mandates thorough malignancy screening ), infections ( Hepatitis B , Hepatitis C, syphilis), autoimmune disease ( Systemic Lupus Erythematosus Class V ), and drugs (NSAIDs, penicillamine, gold).
Renal Biopsy Features:
LM: Diffuse, uniform thickening of the glomerular basement membrane (GBM) without prominent cellular proliferation.
Silver Methenamine Stain: Classic "spike and dome" appearance (subepithelial projections of basement membrane "spikes" extending between non-staining immune deposits).
IF: Diffuse, uniform granular capillary loop deposition of IgG and C3 .
EM: Subepithelial electron-dense immune deposits nestled along the external surface of the lamina densa beneath effaced podocytes.
Management: High rate of spontaneous complete or partial remission (~30%); initial conservative management with ACEi/ARB, statins, and BP control for 6 months. For high-risk disease (persistent severe proteinuria, rising anti-PLA2R titres, or declining eGFR): targeted B-cell depletion with rituximab is now first-line under KDIGO guidelines; alternative is the cyclical Ponticelli regimen (alternating months of cyclophosphamide and oral/IV steroids).
IgA Nephropathy (Berger's Disease)
Epidemiology: The most common primary glomerulonephritis worldwide, especially prevalent in East Asian populations.
Pathophysiology: Multi-hit pathogenesis: genetically susceptible individuals produce excessive circulating galactose-deficient IgA1 (gd-IgA1) . Endogenous IgG or IgA autoantibodies recognize the exposed hinge-region O-glycans, forming circulating immune complexes that deposit in the glomerular mesangium, triggering mesangial cell proliferation and extracellular matrix secretion.
Clinical Presentation: Recurrent episodes of visible, macroscopic haematuria developing synchronously with or 1–2 days after an upper respiratory tract or gastrointestinal viral infection ( "synpharyngitic" macroscopic haematuria ). Between acute episodes, patients exhibit asymptomatic microscopic haematuria with variable proteinuria. Normal serum complement levels (C3 and C4 are typically normal ).
Renal Biopsy Features:
LM: Mesangial hypercellularity and expanded mesangial matrix.
IF (Diagnostic Gold Standard): Intense, predominant granular mesangial deposition of IgA (frequently co-depositing with C3).
EM: Dense immune-type deposits confined to the mesangial matrix.
Oxford Classification (MEST-C Score): Evaluates Mesangial hypercellularity (M), Endocapillary hypercellularity (E), Segmental glomerulosclerosis (S), Tubular atrophy/interstitial fibrosis (T), and Crescents (C).
Therapy: Optimized supportive therapy with ACEi or ARBs titrated to achieve systolic BP < 120 mmHg and proteinuria < 0.5–0.75 g/day; SGLT2 inhibitors (dapagliflozin); targeted-release formulation oral budesonide (Nefecon, acts locally on ileal Peyer's patches); systemic corticosteroids in persistent high-risk disease.
Post-Streptococcal Glomerulonephritis (PSGN)
Epidemiology & Timing: Immune complex-mediated glomerulonephritis developing 1 to 3 weeks following Group A beta-haemolytic streptococcal ( Streptococcus pyogenes ) pharyngitis, or 3 to 6 weeks following streptococcal impetigo/pyoderma.
Clinical Signs: Classical acute nephritic syndrome: "smoky" or "cola-coloured" urine, facial and periorbital oedema, hypertension, and oliguria.
Serological Features: Elevated antistreptolysin O titre (ASOT) (in pharyngitis) or anti-DNase B (in impetigo); markedly depressed serum C3 with normal or mildly low C4 (due to alternative complement pathway consumption). C3 levels normalize spontaneously within 6 to 8 weeks ; failure to normalize beyond 8 weeks mandates renal biopsy to exclude C3 glomerulopathy or lupus nephritis.
Renal Biopsy Features:
LM: Diffuse, global endocapillary proliferative and exudative glomerulonephritis with heavy neutrophilic infiltration.
IF: Coarse granular capillary loop and mesangial deposition of C3 and IgG ("starry sky" appearance).
EM: Characteristic large, subepithelial dome-shaped electron-dense "humps" .
Prognosis & Management: Spontaneous resolution occurs in > 95% of children and the majority of adults. Supportive therapy: salt and water restriction, loop diuretics for hypertension and circulatory overload.